Human TRAIL Monoclonal Antibody
Product Sizes
1 mg
£486.00
YR0110-1MG
5 mg
£1355.00
YR0110-5MG
20 mg
£3531.00
YR0110-20MG
About this Product
- SKU:
- YR0110
- Additional Names:
- Apo-2L|APO2L|CD253|TANCR|TL2|TNLG6A|TRAIL
- Application:
- Block/Inhibit/Neutralise, Cell-based/Functional Assay, ELISA
- Clonality:
- Monoclonal
- Extra Details:
- Drozitumab is a human monoclonal antibody in development for the treatment of cancers. It targets Tumour Necrosis Factor Related Apoptosis-inducing Ligand (TRAIL), whose receptors are found on the surface of many types of malignant cells.Although drozitumab was studied in phase II trials for treating chondrosarcoma, colorectal cancer, non-Hodgkin lymphoma, and non-small cell lung cancer, development has been halted due to lack of clinical response.
- Formulation:
- Purified from cell culture supernatant in an animal-free facility
- Immunogen:
- Human TRAIL
- Isotype:
- IgG1, kappa
- Molecular Weight:
- 150 kDa
- Purity:
- >95%
- Shipping Conditions:
- Blue Ice
- Storage Conditions:
- 2-8[o]C Avoid freeze/thaw cycles., -70[o]C Avoid freeze/thaw cycles.
- Supplier:
- ABclonal Technology
- Type:
- Antibody: Biosimilar Antibody
- Manufacturer's Data Sheet:YR0110
